- 专利标题： Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
-
申请号： US13088044申请日： 2011-04-15
-
公开(公告)号： US08868350B2公开(公告)日： 2014-10-21
- 发明人: Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
- 申请人： Alp Akonur , John Kenneth Leypoldt , Ying-Cheng Lo , Baris Ugur Agar
- 申请人地址： US IL Deerfield CH Glattpark (Opfikon)
- 专利权人： Baxter International Inc.,Baxter Healthcare S.A.
- 当前专利权人： Baxter International Inc.,Baxter Healthcare S.A.
- 当前专利权人地址： US IL Deerfield CH Glattpark (Opfikon)
- 代理机构： K&L Gates LLP
- 主分类号： G01N33/48
- IPC分类号： G01N33/48 ; A61M1/16 ; A61M1/36 ; G06F19/00
摘要：
A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
公开/授权文献
信息查询
